​
​

Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$8.13

52W Range

$4.71 - $9.74

50D Avg

$7.29

200D Avg

$6.07

Market Cap

$1.18B

Avg Vol (3M)

$1.23M

Beta

1.46

Div Yield

-

AUPH Company Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

300

IPO Date

Sep 03, 2014

Website

AUPH Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$158.53M$103.47M$45.49M
License, Collaboration and Royalty Revenue$16.98M--
License-$30.56M$117.00K

Fiscal year ends in Dec 23 | Currency in USD

AUPH Financial Summary

Dec 23Dec 22Dec 21
Revenue$158.53M$134.03M$45.60M
Operating Income$-91.69M$-111.47M$-180.74M
Net Income$-78.02M$-108.18M$-180.97M
EBITDA$-91.69M$-111.47M$-178.64M
Basic EPS$-0.54$-0.76$-1.40
Diluted EPS$-0.54$-0.76$-1.40

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 07, 24 | 11:44 AM
Q2 24Aug 01, 24 | 1:52 PM
Q1 24May 02, 24 | 12:00 AM

Peer Comparison

TickerCompany
AKROAkero Therapeutics, Inc.
TGTXTG Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
BTAIBioXcel Therapeutics, Inc.
EXELExelixis, Inc.
SRPTSarepta Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
VKTXViking Therapeutics, Inc.
AXSMAxsome Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals, Inc.